Welcome, Benjamin Bronfin, MD, Senior Director of Operations Appointed at Recently Acquired Facility
In 2017 Absorption Systems acquired TGA Bioservices, a Boston based facility, to further expand our service offerings. Since then, we have had the honor of welcoming Dr. Benjamin Bronfin as Senior Director of Operations at TGA. Dr. Bronfin has over 20 years of experience in RUO and GLP assay development and validation, including PK, PD, and immunogenicity analysis. He has a medical degree from Omsk Medical Academy, Russia, where he then practiced medicine before moving to Boston to pursue research at Beth Israel Deaconess Medical Center (BIDMC), a Harvard affiliated research hospital. He is proficient with multiple methodologies like ELISA, qPCR, MSD, Western Blot, HPLC, Luminex, RIA, cell-based assay, IHC, and Flow Cytometry.
While working at Harvard’s BIDMC, Dr. Bronfin was responsible for all aspects of gene cloning, protein expression, and characterization.. Following BIDMC, he worked at Cambridge Biomedical, a bioanalytical CRO, in multiple roles including Director of CRO Services. As Director, Dr. Bronfin was responsible for oversight and implementation of assay development, validation and performance in support of clinical trials (pre-clinical through phase IV) and in vitro diagnostic products. He also supervised business development and project life-cycles to ensure compliance with stated IPA requirements, as well as GLP, GCP, and/or CAP/CLIA regulations.
As Senior Director of Operations, he supervises all areas of site operations including laboratory, facility support, client interaction, and business development at TGA.
Benjamin answered a few questions allowing further insights on his career and new role within Absorption Systems:
What made you transfer from practicing medicine to moving into research so early in your career?
I always had a passion for science and research. Bioanalytical testing is becoming increasingly important in patient diagnosis and critical in developing new medicine. I feel privileged to be able to contribute to the development of potential new therapies and playing a role in helping patients.
How have your past positions aligned with TGA’s service portfolio?
Throughout my 20+ year career I have always worked in some form with assay development. My last role as Director of CRO Services provided me with a unique opportunity to work with clients across multiple therapeutic areas in all phases of clinical studies. Having the ability work with clients along the entire spectrum of their regulatory journey provided me with valuable insight into the challenges faced by drug innovators, and an opportunity to collaborate and find innovative solutions.
How do you hope to see customers benefit from TGA’s research capabilities?
TGA has an excellent team of dedicated scientists with a long history of successful assay development and validation. We hope to use our expertise to help our clients’ journey to bring new therapies to patients.